Comparison of Helicobacter pylori eradication rates of standard 14-day quadruple treatment and novel modified 10-day, 12-day and 14-day sequential treatments

European Journal of Internal Medicine

Volumn 25, Issue 3, 2014, Pages 224-229

  Sapmaz, Ferdane ^a   Kalkan, Ismail Hakki ^a   Güliter, Sefa ^a   Atasoy, Pinar ^b  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b KIRIKKALE UNIVERSITY   (Turkey)

Author keywords

Eradication; Failure; H. pylori; Quadruple treatment; Sequential

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; METRONIDAZOLE; RABEPRAZOLE; TETRACYCLINE; ANTIINFECTIVE AGENT; ORGANOMETALLIC COMPOUND; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ADULT; ARTICLE; BACTERIAL CLEARANCE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSGEUSIA; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HUMAN; INTENTION TO TREAT ANALYSIS; INTESTINE FUNCTION DISORDER; MALE; MEDICATION COMPLIANCE; NAUSEA AND VOMITING; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TURKEY (REPUBLIC); DRUG ADMINISTRATION; DRUG COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MIDDLE AGED; PROSPECTIVE STUDY; REMISSION; TIME; TURKEY;

ADULT; ANTI-INFECTIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RABEPRAZOLE; REMISSION INDUCTION; TETRACYCLINE; TIME FACTORS; TURKEY;

EID: 84896393575     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2013.11.006     Document Type: Article

References (53)

1. A. Alakkari, A. Zullo, and H.J. O'Connor Helicobacter pylori and nonmalignant diseases Helicobacter 16 2011 33 37
2. A. Zullo, C. Hassan, F. Cristofari, F. Perri, and S. Morini Gastric low-grade mucosal-associated lymphoid tissue lymphoma: Helicobacter pylori and beyond World J Gastrointest Oncol 2 2010 181 186
3. P. Malfertheiner, F. Megraud, C. O'Morain, F. Bazzoli, E. El-Omar, and D. Graham et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report Gut 56 2007 772 781
4. L.A. Fischbach, K.J. Goodman, M. Feldman, and C. Aragaki Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis Int J Epidemiol 31 2002 128 139
5. P. Malfertheiner, F. Megraud, C. O'Morain, A.P. Hungin, R. Jones, and A. Axon et al. Tytgat G; European Helicobacter pylori Study Group. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report Aliment Pharmacol Ther 16 2002 167 180
6. C.W. Howden, and R.H. Hunt Guidelines for the management of H. pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology Am J Gastroenterol 93 1998 2330 2338
7. M. Sasaki, N. Ogasawara, K. Utsumi, N. Kawamura, T. Kamiya, and H. Kataoka et al. Changes in 12-year first-line eradication rate of Helicobacter pylori based on triple therapy with proton pump Inhibitor, amoxicillin and clarithromycin J Clin Biochem Nutr 47 2010 53 58
8. S.Y. Bang, D.S. Han, C.S. Eun, J.E. Kim, S.B. Ahn, and J.H. Sohn et al. Changing patterns of antibiotic resistance of Helicobacter pylori in patients with peptic ulcer disease Korean J Gastroenterol 50 2007 356 362
9. B.W. Kim, M.G. Choi, S.B. Moon, B.K. Kim, H.S. Chae, and J.K. Kim et al. Pooled analysis of antibiotic therapy for Helicobacter pylori eradication in Korea Korean J Gastroenterol 34 1999 42 49
10. P. Malfertheiner, F. Megraud, C.A. O'Morain, J. Atherton, A.T. Axon, and F. Bazzoli et al. European Helicobacter Study Group. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report Gut 61 2012 646 664
11. A. Zullo, V. Rinaldi, S. Winn, P. Meddi, R. Lionetti, and C. Hassan et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication Aliment Pharmacol Ther 14 2000 715 718
12. Z.A. Cetinkaya, M. Sezikli, F. Guzelbulut, S. Coşgun, S. Düzgün, and O.O. Kurdaş Comparison of the efficacy of the two tetracycline-containing sequential therapy regimens for the eradication of Helicobacter pylori: 5 days versus 14 days amoxicillin Helicobacter 15 2010 143 147
13. M. Yakut, K. Cinar, G. Seven, K. Bahar, and A. Özden Sequential therapy for Helicobacter pylori eradication Turk J Gastroenterol 21 2010 206 211
14. G.J. Valooran, V. Kate, S. Jagdish, and D. Basu Sequential therapy versus standard triple drug therapy for eradication of Helicobacter pylori in patients with perforated duodenal ulcer following simple closure Scand J Gastroenterol 46 2011 1045 1050
15. J.M. Liou, C.C. Chen, M.J. Chen, C.Y. Chang, Y.J. Fang, and J.Y. Lee et al. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial J Antimicrob Chemother 66 2011 1847 1852
16. M.J.R. Janssen, A.H.A.M. Van Oijen, A.L.M. Verbeek, J.B. Jansen, and W.A. De Boer A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole Aliment Pharmacol Ther 15 2001 613 624
17. F. Perri, M.R. Villani, V. Festa, M. Quitadamo, and A. Andriulli Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy' Aliment Pharmacol Ther 15 2001 1023 1029
18. G. Nardone Risk factors for cancer development in Helicobacter pylori gastritis Dig Liver Dis 32 2000 S190 S192
19. J.Q. Huang, and R.H. Hunt The evolving epidemiology of Helicobacter pylori infection and gastric cancer Can J Gastroenterol 17 2003 18B 20B
20. S. Güliter, H. Keleş, Z.N. Ozkurt, D.U. Cengiz, and E. Kolukisa Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of Helicobacter pylori? Turk J Gastroenterol 16 2005 29 33
21. S. Bakir Ozbey, C. Ozakin, and M. Keskin Antibiotic resistance rates of Helicobacter pylori isolates and the comparison of E-test and fluorescent in situ hybridization methods for the detection of clarithromycin resistant strains Mikrobiyol Bul 43 2009 227 234
22. Y. Gumurdulu, E. Serin, B. Ozer, F. Kayaselcuk, K. Ozsahin, and A.M. Cosar et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey World J Gastroenterol 10 2004 668 671
23. A. Aydin, G.F. Onder, U.S. Akarca, F. Tekin, M. Tuncyurek, and A. Musoǧlu The efficacy of two-week therapy with ranitidine bismuth citrate, amoxicillin and clarithromycin on Helicobacter pylori eradication in clarithromycin-resistant and sensitive cases Turk J Gastroenterol 16 2005 203 206
24. X. Calvet, J. Ducons, J. Guardiola, L. Tito, V. Andreu, and F. Bory et al. One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial Aliment Pharmacol Ther 16 2002 1261 1267
25. P.H. Katelaris, G.M. Forbes, N.J. Talley, and B. Crotty A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE study Gastroenterology 123 2002 1763 1769
26. L. Laine, R. Hunt, H. El-Zimaity, B. Nguyen, M. Osato, and J. Spénard et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial Am J Gastroenterol 98 2003 562 567
27. L. Laine Is it time for quadruple therapy to be first line? R.H. Hunt, G.N.J. Tytgat, Helicobacter pylori: basic mechanisms to clinical cure 2002 2002 Kluwer Academic Publishers Dordrecht 347 351
28. J.P. Gisbert, A. Perez-Aisa, L. Rodrigo, J. Molina-Infante, I. Modolell, and F. Bermejo et al. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with Clarithromycin and Levofloxacin) for H. pylori infection Dig Dis Sci 2013 [Epub ahead of print]
29. A. Harris, and J.J. Misiewicz Hitting H. pylori for four Lancet 345 1995 806 807
30. J. Calam Clinicians' guide to Helicobacter pylori 1996 Chapman & Hall London
31. A. Uygun, A.M. Ozel, O. Yildiz, M. Aslan, Z. Yesilova, and A. Erdil et al. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy J Gastroenterol Hepatol 23 1 2008 42 45
32. W.A. De Boer How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients J Clin Gastroenterol 22 1996 313 316
33. R.H. Phillips, M.W. Whitehead, L.A. Doig, C.E. Sieniawska, H.T. Delves, and R.P. Thompson et al. Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe? Helicobacter 6 2001 151 156
34. G. Onder, A. Aydin, U. Akarca, F. Tekin, O. Ozutemiz, and T. Ilter High Helicobacter pylori resistance rate to clarithromycin in Turkey J Clin Gastroenterol 41 8 2007 747 750
35. O. Sezgin, G. Aslan, E. Altintaş, S. Tezcan, M.S. Serin, and G. Emekdaş Detection of point mutations on 23S rRNA of Helicobacter pylori and resistance to clarithromycin with PCR-RFLP in gastric biopsy specimens in Mersin, Turkey Turk J Gastroenterol 19 2008 163 167
36. U. Caǧdaş, F. Otaǧ, S. Tezcan, O. Sezgin, G. Aslan, and G. Emekdaş et al. Detection of Helicobacter pylori and antimicrobial resistance in gastric biopsy specimens Mikrobiyol Bul 46 2012 398 409
37. A.S. Koksal, F.O. Onder, S. Torun, E. Parlak, A. Sayilir, and O. Tayfur et al. Twice a day quadruple therapy for the first-line treatment of Helicobacter pylori in an area with a high prevalence of background antibiotic resistance Acta Gastroenterol Belg 76 2013 34 37
38. B. Ergul, Z. Dogan, M. Sarikaya, and L. Filik The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study Helicobacter 18 2013 454 458
39. V. De Francesco, A. Zullo, M. Margiotta, S. Marangi, O. Burattini, and P. Berloco et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure Aliment Pharmacol Ther 19 2004 407 414
40. A. Zullo, D. Vaira, N. Vakil, C. Hassan, L. Gatta, and C. Ricci et al. High eradication rates of Helicobacter pylori with a new sequential treatment Aliment Pharmacol Ther 17 2003 719 726
41. R. Francavilla, E. Lionetti, S.P. Castellaneta, A.M. Magistà, G. Boscarelli, and D. Piscitelli et al. Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial Gastroenterology 129 2005 1414 1419
42. G. Scaccianoce, C. Hassan, A. Panarese, D. Piglionica, S. Morini, and A. Zullo Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen Can J Gastroenterol 20 2006 113 117
43. L. Gatta, N. Vakil, G. Leandro, F. Di Mario, and D. Vaira Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children Am J Gastroenterol 104 2009 3069 3079
44. P. Unge Review of Helicobacter pylori eradication regimens Scand J Gastroenterol 31 1996 74 81
45. K. Murakami, T. Fujioka, T. Okimoto, R. Sato, M. Kodama, and M. Nasu Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy Int J Antimicrob Agents 19 2002 67 70
46. T. Calhan, R. Kahraman, A. Sahin, E. Senates, H.L. Doganay, and E. Kanat et al. Efficacy of two levofloxacin-containing second-line therapies for Helicobacter pylori: a pilot study Helicobacter 18 2013 378 383
47. M.S. Kim, N. Kim, S.E. Kim, H.J. Jo, C.M. Shin, and Y.S. Park et al. Long-term follow up Helicobacter pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy BMC Gastroenterol 13 2013 138
48. J.P. Gisbert, and J.M. Pajares Treatment of Helicobacter pylori infection: the past and the future Eur J Intern Med 21 2010 357 359
49. A. Zullo, C. Hassan, L. Ridola, V. De Francesco, V. De Francesco, and D. Vaira Standard triple and sequential therapies for Helicobacter pylori eradication: an update Eur J Intern Med 24 2013 16 19
50. E.R. Greenberg, G.L. Anderson, D.R. Morgan, J. Torres, W.D. Chey, and L.E. Bravo et al. 14-Day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial Lancet 378 2011 507 514
51. P. Albrecht, M. Kotowska, and H. Szajewska Sequential therapy compared with standard triple therapy for Helicobacter pylori eradication in children: a double-blind, randomized, controlled trial J Pediatr 159 2011 45 49
52. M.S. Osato, R. Reddy, and D.Y. Graham Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States Int J Antimicrob Agents 12 1999 341 347
53. H. Lee, and J.J. Kim Impact of metronidazole resistance on eradication rate for Helicobacter pylori Korean J Gastroenterol 46 2005 142 145